The Next Generation for Qiagen NV (QGEN)’s Next-Gen Sequencing?

Page 1 of 2

Patient-specific pharmacology used to be a futuristic dream for researches and physicians, but the Human Genome Project has placed the framework for this revolution in patient care at our fingertips.

In research labs across the country, genomic studies are uncovering the small genetic changes that underlie countless diseases.  In the clinic, rapid genetic sequencing is contributing to unparalleled diagnostic capabilities.  But without the software to analyze sequencing results, researchers are left with an indecipherable jumble of A’s, T’s, G’s, and C’s.  UnitedHealth Group Inc. (NYSE:UNH) estimates that the market for decoding genes from individual patients may grow to $25 billion from $5 billion in the next decade.

Qiagen NV (NASDAQ:QGEN)

In its 2012 annual report released on May 15, Qiagen NV (NASDAQ:QGEN) stresses its plan to grow sustainably by reinforcing a “sample-to-results platform” with streamlined genomic analysis.  Qiagen is already an established supplier of laboratory consumables used for various genetic techniques in research, clinical, and forensic settings.

However, the sequester and NIH spending cuts have hurt Qiagen’s revenues from academic institutions, which fell 4% in the last quarter.  It is therefore appropriate that Qiagen NV (NASDAQ:QGEN) focus more heavily on molecular diagnostics and clinical tools that improve patient specific pharmacology.  Diagnostics accounted for 50% of revenue last quarter, and its Therascreen platform of diagnostics is expanding to new diseases including non-small cell lung cancer, pending FDA approval.

Riding the demand wave

Qiagen first entered the “next generation sequencing” field when it acquired Intelligent Bio-systems in 2012.  It recently made another move to profit from the growing demand for accessible, efficient genomic analysis software with its acquisition of privately owned Ingenuity Systems.  Ingenuity boasts a powerful literature-based network for genomic analysis, with customers ranging from big pharma to academia.

The acquisition of Ingenuity Systems accomplishes a major component of Qiagen NV (NASDAQ:QGEN)’s growth strategy – it enhances the sample-to-results workflow that seeks to provide an ecosystem of sample preparation, data collection, and analysis.  The question is: can this ecosystem compete with similar services offered by other contract research companies with sequencing services?

Can Qiagen keep pace?

Qiagen NV (NASDAQ:QGEN)’s acquisition is a clear attempt to keep pace with Thermo Fisher Scientific Inc. (NYSE:TMO), which recently acquired Life Technologies Corp. (NASDAQ:LIFE) for $13.6 billion.  With Life Technologies comes its Ion Torrent sequencing technology and Applied Biosystems’ analytical tools.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!